Podcast episode 109 (in German)
Chelation therapy – the lead falls, the heart attacks do not
October 17, 2026
An infusion course lowers lead in the blood by a good 60 percent, and yet those treated have just as many heart attacks, strokes and deaths as on placebo. This episode explains how both can be in the same trial and where chelation therapy keeps its established place.
What it is about
Chelation therapy means: an EDTA infusion binds metal ions, which are then excreted via the kidneys. In confirmed metal poisoning this is established, prescription-only and effective — the episode does not question that. It is about the more than 50-year-old idea that the same procedure clears calcified vessels again. A government-funded trial from 2013 seemed to support this, especially in people with diabetes. The follow-up trial tested exactly this group again, large enough to find the effect again. The result is a rarely clean finding: lead falls measurably, events do not, measured in the same people under the same study protocol.
Key points
- The 2013 trial with 1,708 people after a heart attack at 134 centers found the combined endpoint in 26 percent of those treated versus 30 percent on placebo, that is, 18 percent fewer.
- Because of the interim analyses, the threshold for statistical significance was 0.036; the result was 0.035 — passed by one thousandth.
- During the trial, 289 participants withdrew their consent, 17 percent, and unevenly distributed: 115 on EDTA, 174 on placebo. What became of them is unknown.
- In the prespecified subgroup of 633 people with diabetes, the rate was 25 versus 38 percent, hazard ratio 0.59; in the 1,075 without diabetes there was no effect.
- The follow-up trial in exactly this group, 1,000 people allocated at 88 centers with 40 weekly infusions, found events in 35.6 versus 35.7 percent, hazard ratio 0.93, p equal to 0.53.
- Lead fell from a median of 9.03 to 3.46 micrograms per liter, on placebo only from 9.3 to 8.7; mortality was 17.4 versus 17.6 percent.
- The second study arm with high-dose vitamins and minerals from 28 components came to 175 versus 175 events, hazard ratio 0.99.
Where the data stop
None of these figures apply to people without symptoms who have been told they have a heavy metal burden. Both trials studied only people after a heart attack, the second additionally only those with diabetes. For detoxification in a claimed burden there is no trial with hard endpoints, neither a positive nor a negative one. Anyone who says “disproven” here is saying too much — and so is anyone who says “so it might help after all”.
On risk, precise wording pays off. The US Centers for Disease Control and Prevention reviewed 3 deaths between 2003 and 2005, all due to calcium deficiency with cardiac arrest, because 2 EDTA salts were mixed up — a mix-up risk, not a side effect. The US Food and Drug Administration also lists dehydration, kidney failure and deaths — and the easily overlooked harm that an effective treatment is delayed. The score therefore shows a 7 for human evidence next to a 3 for mechanism: well studied, effect not confirmed.
Listen (in German)
Listen on Spotify Listen on Apple Podcasts Listen on Amazon Music
Published on October 17, 2026.
The topic in the database
- Infusion of binding agents (e.g. EDTA) that bind heavy metals in the blood and remove them – medically used in confirmed poisoning, otherwise controversial.Chelation therapy
All episodes in the app (German)
Information only, not medical advice and not a usage or dosage recommendation. Prescription-only and unapproved substances belong in the hands of a physician. Last updated: 2026-09-22.